JP2017523776A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523776A5
JP2017523776A5 JP2017502121A JP2017502121A JP2017523776A5 JP 2017523776 A5 JP2017523776 A5 JP 2017523776A5 JP 2017502121 A JP2017502121 A JP 2017502121A JP 2017502121 A JP2017502121 A JP 2017502121A JP 2017523776 A5 JP2017523776 A5 JP 2017523776A5
Authority
JP
Japan
Prior art keywords
patient
gene
expression
rpl13a
ets1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017502121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523776A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/040408 external-priority patent/WO2016011052A1/en
Publication of JP2017523776A publication Critical patent/JP2017523776A/ja
Publication of JP2017523776A5 publication Critical patent/JP2017523776A5/ja
Pending legal-status Critical Current

Links

JP2017502121A 2014-07-14 2015-07-14 膠芽腫の診断方法及びその治療用組成物 Pending JP2017523776A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462024244P 2014-07-14 2014-07-14
US62/024,244 2014-07-14
PCT/US2015/040408 WO2016011052A1 (en) 2014-07-14 2015-07-14 Diagnostic methods and compositions for treatment of glioblastoma

Publications (2)

Publication Number Publication Date
JP2017523776A JP2017523776A (ja) 2017-08-24
JP2017523776A5 true JP2017523776A5 (enExample) 2018-08-30

Family

ID=53762365

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502121A Pending JP2017523776A (ja) 2014-07-14 2015-07-14 膠芽腫の診断方法及びその治療用組成物

Country Status (5)

Country Link
US (1) US10208355B2 (enExample)
EP (1) EP3169801A1 (enExample)
JP (1) JP2017523776A (enExample)
CN (1) CN106460067A (enExample)
WO (1) WO2016011052A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
CN110023762A (zh) * 2016-12-01 2019-07-16 参天制药株式会社 用于预测利用抗vegf药物对渗出性年龄相关性黄斑变性进行的处置的有效性的方法
CN108728533B (zh) * 2017-04-20 2022-06-14 常青 用于髓母细胞瘤分子分型的基因群以及snca基因作为4型髓母细胞瘤的生物标志物的用途
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
EP3893902B1 (en) 2018-12-11 2024-10-23 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of pd-l1 activity or expression for use in the treatment of serrated colorectal cancer
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
DE102020004924A1 (de) * 2020-08-13 2022-02-17 Daimler Ag Bodenstruktur für eine Karosserie eines Fahrzeugs, Karosserie für ein Fahrzeug sowie Fahrzeug
KR102878653B1 (ko) * 2022-04-08 2025-10-31 연세대학교 산학협력단 유전자로 정의된 암기원세포, 및 이의 분류방법
KR102878656B1 (ko) * 2022-04-08 2025-10-31 연세대학교 산학협력단 유전자로 정의된 암기원세포, 및 이의 분류방법

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
EP0666868B2 (en) 1992-10-28 2006-06-14 Genentech, Inc. Use of anti-VEGF antibodies for the treatment of cancer
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-vegf 항체
CN101665536B (zh) 1997-04-07 2013-07-03 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP2003529774A (ja) 2000-03-31 2003-10-07 ジェネンテック・インコーポレーテッド 遺伝子発現を検出し定量するための構成物及び方法
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス,インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
JP4731793B2 (ja) 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド 合成抗体ファージライブラリー
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
KR20160014775A (ko) 2003-05-30 2016-02-11 제넨테크, 인크. 항-vegf 항체를 사용한 치료
PT3095793T (pt) 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060008823A1 (en) 2004-05-12 2006-01-12 Kemp Jennifer T DNA profiling and SNP detection utilizing microarrays
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
BRPI0620695A2 (pt) * 2005-12-16 2011-11-22 Genentech, Inc método para tratar um tumor do tipo glioma, métodos de prognóstico e/ou diagnóstico de glioma, método de monitoramento ou diagnóstico, método para inibir o tamanho ou crescimento de um tumor do tipo glioma, métodos para tratar terapeuticamente, método para determinar o nìvel de expressão de marcadores determinantes de glioma ("gdm") de pn, prolif ou mes, método para prognosticar o tempo de sobrevida, método para diagnosticar a severidade de um tumor do tipo glioma e uso
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2132336A1 (en) 2007-03-02 2009-12-16 Board of Regents, The University of Texas System Multigene assay to predict outcome in an individual with glioblastoma
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
AU2010239368A1 (en) 2009-04-20 2011-11-10 Genentech, Inc. Adjuvant cancer therapy
EP2464744A1 (en) * 2009-08-14 2012-06-20 F. Hoffmann-La Roche AG Biological markers for monitoring patient response to vegf antagonists
CN110227154A (zh) 2010-02-23 2019-09-13 霍夫曼-拉罗奇有限公司 用于治疗卵巢癌的抗血管发生疗法
WO2012027379A2 (en) 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
EA025926B1 (ru) * 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест на рак
BR112014017320A2 (en) * 2012-01-13 2018-05-29 Genentech, Inc method for determining whether a patient is prone to respond to treatment with a vegf antagonist, method for optimizing the therapeutic efficacy of a vegf antagonist, method for selecting a therapy, method for identifying a biomarker, and method for diagnosing an angiogenic disorder
MX2014011582A (es) * 2012-03-30 2014-11-21 Genentech Inc Metodos y composiciones de diagnostico para el tratamiento de cancer.
GB201207722D0 (en) * 2012-05-02 2012-06-13 Bergenbio As Method
SG11201500903XA (en) * 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
AU2013353839A1 (en) * 2012-12-03 2015-06-18 Almac Diagnostics Limited Molecular diagnostic test for cancer
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma

Similar Documents

Publication Publication Date Title
JP2017523776A5 (enExample)
Hamid et al. Intratumoral immunotherapy—update 2019
US20250051392A1 (en) Bicyclic peptide ligands specific for nectin-4
Spira et al. OA03. 03 Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01 phase 1 study
Chen et al. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes
RU2016111161A (ru) Диагностические способы и композиции для лечения глиобластомы
Wick et al. Current status and future directions of anti-angiogenic therapy for gliomas
JP6857498B2 (ja) 癌を処置するための併用方法
Sheahan et al. Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review
Kordbacheh et al. Current and emerging molecular therapies for head and neck squamous cell carcinoma
JP2015512612A5 (enExample)
Tezuka et al. Potential anti-tumor effect of IFN-λ2 (IL-28A) against human lung cancer cells
JP2024527109A (ja) Kras変異体がんの処置のための方法および組成物
JP6337258B2 (ja) 腫瘍免疫又は感染免疫を増強させる免疫増強剤
US20240408071A1 (en) Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer
KR20210053242A (ko) 항암제 내성을 완화하고 항암제의 민감성을 강화하기 위한 약학적 조성물 및 그 용도
CN103338779B (zh) 分枝杆菌w在制备治疗癌症药物中的用途
Sun et al. 1320TiP The efficacy and safety of stereotactic body radiation therapy (SBRT) plus toripalimab with or without bevacizumab as second-line treatment for advanced non-small cell lung cancer (NSCLC): A prospective, multicenter, open-label, phase II study
Tang et al. Oncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation
CN110494137A (zh) 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途
Moon et al. An examination of the mechanisms driving the therapeutic effects of an AAV expressing a soluble variant of VEGF receptor-1
Galimberti Preliminary characterization of CR13626, a novel tyrosine kinase inhibitor for the treatment of glioblastoma.
MM et al. Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers
Reck et al. 1420TiP A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC)
Lisberg et al. 1199TiP Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC